Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
|Articles|May 19, 2015
- Genitourinary (Issue 2)
- Issue 2
Trends in PSA Utilization in Primary Care Physicians
Author(s)Ryan Werntz, MD
Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.
Advertisement
Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.
<<<
Articles in this issue
over 11 years ago
Use of ARN-509 in Prostate Cancerover 11 years ago
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPCover 11 years ago
Study Illuminates Role of AR-V7 in Carcinogenesisover 11 years ago
PSA Screening Drops 50% Following USPSTF Recommendationover 11 years ago
Urine-Based Diagnostic Effectively Identifies Prostate Cancerover 11 years ago
AR-V7 as a Biomarker in CRPCAdvertisement
Related to this article
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5